HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.

Haase VH
Hemodial Int. 2017 21 Suppl 1: S110-S124

PMID: 28449418 · PMCID: PMC5526677 · DOI:10.1111/hdi.12567

A classic response to systemic hypoxia is the increase in red blood cell production. This response is controlled by the prolyl hydroxylase domain/hypoxia-inducible factor (HIF) pathway, which regulates a broad spectrum of cellular functions. The discovery of this pathway as a key regulator of erythropoiesis has led to the development of small molecules that stimulate the production of endogenous erythropoietin and enhance iron metabolism. This review provides a concise overview of the cellular and molecular mechanisms that govern HIF-induced erythropoietic responses and provides an update on clinical experience with compounds that target HIF-prolyl hydroxylases for anemia therapy.

© 2017 International Society for Hemodialysis.

MeSH Terms (13)

Anemia Barbiturates Clinical Trials as Topic Erythropoiesis Erythropoietin Glycine Humans Hypoxia-Inducible Factor-Proline Dioxygenases Iron Isoquinolines Picolinic Acids Prolyl-Hydroxylase Inhibitors Renal Dialysis

Connections (1)

This publication is referenced by other Labnodes entities: